Generating the First Therapeutic Treatments for Viral Diseases

Excision BioTherapeutics’ rapidly progressing pipeline comprises various programs targeting viral infectious diseases, including Herpes Simplex Viruses (HSV 1&2), Hepatitis B, and Human Immunodeficiency Virus (HIV).

Our Pipeline

Pipeline image. Info is available below.

Our Pipeline

Other

EBT-101

HIV AAV9 Cas9 dual gRNA Therapeutic

Discovery/Validation Preclinical Cleared IND Clinical Trials
Discovery/Validation Phase complete
Preclinical Phase complete
Cleared IND Phase in progress
Clinical Trials Phase not started

EBT-104

HSV AAV CRISPR/Cas dual gRNA Therapeutic

Discovery/Validation Preclinical Cleared IND Clinical Trials
Discovery/Validation Phase complete
Preclinical Phase in progress
Cleared IND Phase not started
Clinical Trials Phase not started

EBT-107

HBV non-viral CRISPR/Cas dual gRNA Therapeutic

Discovery/Validation Preclinical Cleared IND Clinical Trials
Discovery/Validation Phase in progress
Preclinical Phase not started
Cleared IND Phase not started
Clinical Trials Phase not started

EBT-104

Targeting Herpes Virus-infected cells in peripheral nervous system (PNS) ganglia.

Learn More

EBT-107

Targeting Hepatitis B-infected cells in the liver.

Learn More

EBT-101

Targeting HIV-infected cells in viral tissue reservoirs and systemic circulation.

Learn More